Sort
15,273 grants matching “antimicrobial resistance”
OUTBREAKS CAUSED BY VIRULENT AEROMONAS HYDROPHILA (VAH) SINCE 2009 RESULTED IN SIGNIFICANT LOSSES OF CATFISH FROM U.S. AQUACULTURE. THIS DISEASE IS A VERY HIGH PRIORITY FOR THE CATFISH INDUSTRY; IT HAS HAD A SERIOUS IMPACT ON THE REGION OF WEST ALABAMA AND EAST MISSISSIPPI, AND IT HAS BECOME THE MOST COMMONLY DIAGNOSED DISEASE IN THE MISSISSIPPI STATE UNIVERSITY AND AUBURN UNIVERSITY FISH DIAGNOSTIC LABORATORIES SERVING THESE REGIONS. THERE ARE LIMITATIONS IN THE CURRENT THERAPEUTIC AND PREVENTATIVE STRATEGIES AGAINST VAH. THE PROBLEM IS EXACERBATED BY A. HYDROPHILA STRAINS RESISTANT TO THE FDA APPROVED ANTIMICROBIAL (TERRAMYCIN®). THUS, IN THIS RESEARCH I AIM TO DEVELOP A DISEASE PREVENTION METHOD. SPECIFICALLY, THIS PROJECT WILL FOCUS ON VACCINE DEVELOPMENT AND EFFICACY EVALUATION IN CHANNEL CATFISH. OUR PRELIMINARY DATA REVEALED THAT RECOMBINANT VAH SURFACE PROTEINS (FIM, FIMMRFG, ATPASE, TDR, AND OMPA1) ARE EFFECTIVE IN PROTECTING CATFISH AGAINST MAS. FURTHERMORE, LIVE ATTENUATED EDWARDSIELLA ICTALURI VACCINE STRAIN ESC-NDKL1 IS AN EFFECTIVE CARRIER FOR THESE ANTIGENS USING A RECOMBINANT EXPRESSION SYSTEM. THE CENTRAL HYPOTHESIS IS THAT EXPRESSION OF VAH SURFACE PROTEINS IN A LIVE ATTENUATED E. ICTALURI VACCINE STRAIN WILL PROVIDE SIGNIFICANT PROTECTION AGAINST BOTH MAS CAUSED BY VAH AND ESC CAUSED BY E. ICTALURI, AND THAT VAH STIMULATES SIGNIFICANT INFLAMMATION IN THE ADAPTIVE IMMUNE RESPONSE IN CATFISH. IN THIS PROJECT, I WILL COMPLETE TWO OBJECTIVES: 1) CONSTRUCTION AND EVALUATION OF A RECOMBINANT LIVE ATTENUATED VACCINE STRAIN AS A DUAL STRATEGY TO PREVENT MAS AND ESC. THE GOAL IS TO DEVELOP AND EVALUATE STABLE RECOMBINANT ESC-NDKL1 STRAINS EXPRESSING ONE, TWO, OR THREE VAH SURFACE ANTIGENS. 2) DETERMINE EFFECTS OF VAH STRAIN ML09-119 ON THE CATFISH IMMUNE RESPONSE. THE GOAL IS TO DETERMINE THE ROLE OF INNATE AND ADAPTIVE IMMUNE COMPONENTS IN THE CHANNEL CATFISH RESPONSE TO VAH. THIS RESEARCH WILL YIELD AN IMPORTANT TOOL AND INFORMATION TO HELP COMBAT TWO DISEASES THAT HEAVILY IMPACT THE CATFISH INDUSTRY.
$100,220Mississippi State University · · FY2022 · National Institute of Food and Agriculture
Enhancing In Vitro Antimicrobial Activity of Common Antibiotics with Cyclopeptide
$100,166Maria Ngu-Schwemlein · Winston-Salem State University · SC3 · FY2012 · GM
Photoactivated Antimicrobial Collagen
$100,085Barbara Ann Soltz · Conversion Energy Enterprises · R43 · FY2009 · GM
A DRUG RELEASING URINARY CATHETER
$100,045Whalen Biomedical, Inc · R43 · FY2000 · DK
SBIR Phase I: Early Growth Metabolic Responses of Mycobacteria
$100,000Ronald J Rieder · Biosense Technologies Inc. · · FY2006 · TIP
Development of B-Lock, an antibiofilm catheter lock product
$100,000Krzysztof Appelt · Great Lakes Pharmaceuticals, Inc. · R44 · FY2008 · HL
ANTIMICROBIAL PEPTIDES TO TREAT BACTERIAL KERATITIS
$100,000Bio-Concept Laboratories, Inc. · R43 · FY2004 · EY
Phase 2 Study of PA-824 for Treatment of Pulmonary Tuberculosis
$100,000Kelly E. Dooley · Johns Hopkins University · R01 · FY2021 · FD
Macrolide Discovery through Glycosylation
$100,000Optimer Pharmaceuticals, Inc. · R43 · FY2004 · AI
Infection and encrustation resistant stent materials
$100,000Innovative Chemical/Environmental Tech · R43 · FY2002 · DK
Oral care treatment for mobility-impaired patients
$100,000Sheldon E Broedel · Athena Environmental Science, Inc. · R43 · FY2011 · DE
Georgia: NARMS Retail Meat RFA- PAR-16-099 NARMS Cooperative Agreement Program
$100,000Tonia Parrott · Georgia State Departmentof Public Health · U01 · FY2020 · FD
Peptide Derivatives to treat Urinary Tract Infections
$100,000Chaperone Technologies, Inc. · R43 · FY2003 · DK
Planning Grant: Engineering Research Center for Innovative Materials and Processes for Antimicrobial Control Technologies (IMPACT)
$100,000Dacheng Ren · Syracuse University · · FY2019 · ENG
Novel Broad/Narrow-Spectrum Antibiotics Against Bacteria
$100,000Mycosynthetix, Inc. · R43 · FY2004 · AI
Triple action chimera: eradication of nasal S. aureus by cell wall hydrolases
$100,000David Matthew Donovan · U.S. Agricultural Research Center · R01 · FY2008 · AI
Enhancing Capability and Capacity of MarylandâÂÂs Laboratory to Conduct Surveillance of Antibiotic Resistance Pathogens in Selected Retail Foods
$100,000Pongpan Laksanalamai · Maryland State Department Of Health · U01 · FY2019 · FD
IDENTIFICATION OF ANTIMICROBIAL AGENTS AND TARGETS
$100,000Pinnacle Pharmaceuticals · R43 · FY2001 · AI
ADVANCING INFECTIOUS DISEASES DETECTION AND RESPONSE IN INDONESIA THROUGH IMPROVING PUBLIC HEALTH LABORATORY CAPACITY
$100,000Agus Suprapto · Kementerian Kesehatan Ri · U01 · FY2020 · GH
Understanding Evolution of Protein Function Through Design
$100,000Ivan V Korendovych · Syracuse University · R35 · FY2018 · GM
Combinatorial Carbohydrate Libraries for Drug Discovery
$100,000Isis Pharmaceuticals, Inc. · R41 · FY2001 · AI
SBIR Phase I: Rapid Antibiotic Susceptibility Testing
$100,000Ronald J Rieder · Biosense Technologies Inc. · · FY2003 · TIP
Antimicrobial Coating for Biofilm Inhibition
$100,000Biomedical Development Corporation · R41 · FY2002 · AI
Target and antibiotic discovery in Bacillus anthracis
$100,000Elitra Pharmaceuticals, Inc. · R43 · FY2002 · AI
SBIR Phase I: Biocidal Textiles for Active Infection Control
$100,000Nina M Lamba · Ccl Biomedical, Inc · · FY2007 · TIP